Cilostazol combats lipopolysaccharide‐induced hippocampal injury in rats: Role of AKT/GSK3β/CREB curbing neuroinflammation

Research output: Contribution to journalArticleResearchpeer review

Authors

  • Doaa Abou El-ezz
  • Waleed Aldahmash
  • Tuba Esatbeyoglu
  • Sherif M. Afifi
  • Marawan Abd Elbaset
  • Norsharina Ismail (Editor)

External Research Organisations

  • October 6 University
  • King Saud University
  • University of Bologna
  • National Research Centre (NRC)
View graph of relations

Details

Original languageEnglish
Article number3465757
Number of pages10
JournalAdvances in Pharmacological and Pharmaceutical Sciences
Volume2024
Issue number1
Publication statusPublished - 26 Sept 2024

Abstract

Neuroinflammation is important in the pathophysiology of several degenerative brain disorders. This study looked at the potential neuroprotective benefits of cilostazol, a phosphodiesterase inhibitor, against LPS-induced hippocampus damage in rodents and the principal molecular involvement of AKT/GSK3β/CREB signaling pathways. Behavioral tests revealed that cilostazol successfully corrected LPS-induced neurobehavioral impairments. Furthermore, cilostazol therapy lowered hippocampal levels of amyloid beta 1-42 (Aβ1-42) and p-Tau protein, both of which are critical pathological indicators of neurodegenerative disorders. Furthermore, cilostazol administration suppressed LPS-induced rises in hippocampus caspase-3 and NF-B levels while elevating rat B-cell/lymphoma 2 (BCL2) and brain-derived neurotrophic factor (BDNF) levels, which are implicated in neuronal survival and synaptic plasticity. Cilostazol treatment also restored the decreased phosphorylation of protein kinase B (p-AKT) and reduced the elevated levels of phosphorylated glycogen synthase kinase-3 beta (p-GSK3β) and cAMP response element-binding protein (CREB) in the hippocampus of LPS-Treated rats. Histopathological examination revealed that cilostazol ameliorated LPS-induced brain damage with reduced neuronal loss and gliosis. Immunohistochemistry analysis showed a decrease in Iba-1 expression, indicating a reduction in microglial activation in the cilostazol-Treated group compared to the LPS group. The findings advocate that cilostazol exerts neuroprotective effects against LPS-induced hippocampal injury by modulating the AKT/GSK3β/CREB pathway and curbing neuroinflammation. Cilostazol may hold promise as a therapeutic agent for neuroinflammatory conditions associated with neurodegenerative diseases.

ASJC Scopus subject areas

Cite this

Cilostazol combats lipopolysaccharide‐induced hippocampal injury in rats: Role of AKT/GSK3β/CREB curbing neuroinflammation. / El-ezz, Doaa Abou; Aldahmash, Waleed; Esatbeyoglu, Tuba et al.
In: Advances in Pharmacological and Pharmaceutical Sciences, Vol. 2024, No. 1, 3465757, 26.09.2024.

Research output: Contribution to journalArticleResearchpeer review

El-ezz, DA, Aldahmash, W, Esatbeyoglu, T, Afifi, SM, Elbaset, MA & Ismail, N (ed.) 2024, 'Cilostazol combats lipopolysaccharide‐induced hippocampal injury in rats: Role of AKT/GSK3β/CREB curbing neuroinflammation', Advances in Pharmacological and Pharmaceutical Sciences, vol. 2024, no. 1, 3465757. https://doi.org/10.1155/2024/3465757
El-ezz, D. A., Aldahmash, W., Esatbeyoglu, T., Afifi, S. M., Elbaset, M. A., & Ismail, N. (Ed.) (2024). Cilostazol combats lipopolysaccharide‐induced hippocampal injury in rats: Role of AKT/GSK3β/CREB curbing neuroinflammation. Advances in Pharmacological and Pharmaceutical Sciences, 2024(1), Article 3465757. https://doi.org/10.1155/2024/3465757
El-ezz DA, Aldahmash W, Esatbeyoglu T, Afifi SM, Elbaset MA, Ismail N, (ed.). Cilostazol combats lipopolysaccharide‐induced hippocampal injury in rats: Role of AKT/GSK3β/CREB curbing neuroinflammation. Advances in Pharmacological and Pharmaceutical Sciences. 2024 Sept 26;2024(1):3465757. doi: 10.1155/2024/3465757
El-ezz, Doaa Abou ; Aldahmash, Waleed ; Esatbeyoglu, Tuba et al. / Cilostazol combats lipopolysaccharide‐induced hippocampal injury in rats : Role of AKT/GSK3β/CREB curbing neuroinflammation. In: Advances in Pharmacological and Pharmaceutical Sciences. 2024 ; Vol. 2024, No. 1.
Download
@article{c8cd47b8fa31475bb8cf322c34cfc1f9,
title = "Cilostazol combats lipopolysaccharide‐induced hippocampal injury in rats: Role of AKT/GSK3β/CREB curbing neuroinflammation",
abstract = "Neuroinflammation is important in the pathophysiology of several degenerative brain disorders. This study looked at the potential neuroprotective benefits of cilostazol, a phosphodiesterase inhibitor, against LPS-induced hippocampus damage in rodents and the principal molecular involvement of AKT/GSK3β/CREB signaling pathways. Behavioral tests revealed that cilostazol successfully corrected LPS-induced neurobehavioral impairments. Furthermore, cilostazol therapy lowered hippocampal levels of amyloid beta 1-42 (Aβ1-42) and p-Tau protein, both of which are critical pathological indicators of neurodegenerative disorders. Furthermore, cilostazol administration suppressed LPS-induced rises in hippocampus caspase-3 and NF-B levels while elevating rat B-cell/lymphoma 2 (BCL2) and brain-derived neurotrophic factor (BDNF) levels, which are implicated in neuronal survival and synaptic plasticity. Cilostazol treatment also restored the decreased phosphorylation of protein kinase B (p-AKT) and reduced the elevated levels of phosphorylated glycogen synthase kinase-3 beta (p-GSK3β) and cAMP response element-binding protein (CREB) in the hippocampus of LPS-Treated rats. Histopathological examination revealed that cilostazol ameliorated LPS-induced brain damage with reduced neuronal loss and gliosis. Immunohistochemistry analysis showed a decrease in Iba-1 expression, indicating a reduction in microglial activation in the cilostazol-Treated group compared to the LPS group. The findings advocate that cilostazol exerts neuroprotective effects against LPS-induced hippocampal injury by modulating the AKT/GSK3β/CREB pathway and curbing neuroinflammation. Cilostazol may hold promise as a therapeutic agent for neuroinflammatory conditions associated with neurodegenerative diseases.",
author = "El-ezz, {Doaa Abou} and Waleed Aldahmash and Tuba Esatbeyoglu and Afifi, {Sherif M.} and Elbaset, {Marawan Abd} and Norsharina Ismail",
year = "2024",
month = sep,
day = "26",
doi = "10.1155/2024/3465757",
language = "English",
volume = "2024",
number = "1",

}

Download

TY - JOUR

T1 - Cilostazol combats lipopolysaccharide‐induced hippocampal injury in rats

T2 - Role of AKT/GSK3β/CREB curbing neuroinflammation

AU - El-ezz, Doaa Abou

AU - Aldahmash, Waleed

AU - Esatbeyoglu, Tuba

AU - Afifi, Sherif M.

AU - Elbaset, Marawan Abd

A2 - Ismail, Norsharina

PY - 2024/9/26

Y1 - 2024/9/26

N2 - Neuroinflammation is important in the pathophysiology of several degenerative brain disorders. This study looked at the potential neuroprotective benefits of cilostazol, a phosphodiesterase inhibitor, against LPS-induced hippocampus damage in rodents and the principal molecular involvement of AKT/GSK3β/CREB signaling pathways. Behavioral tests revealed that cilostazol successfully corrected LPS-induced neurobehavioral impairments. Furthermore, cilostazol therapy lowered hippocampal levels of amyloid beta 1-42 (Aβ1-42) and p-Tau protein, both of which are critical pathological indicators of neurodegenerative disorders. Furthermore, cilostazol administration suppressed LPS-induced rises in hippocampus caspase-3 and NF-B levels while elevating rat B-cell/lymphoma 2 (BCL2) and brain-derived neurotrophic factor (BDNF) levels, which are implicated in neuronal survival and synaptic plasticity. Cilostazol treatment also restored the decreased phosphorylation of protein kinase B (p-AKT) and reduced the elevated levels of phosphorylated glycogen synthase kinase-3 beta (p-GSK3β) and cAMP response element-binding protein (CREB) in the hippocampus of LPS-Treated rats. Histopathological examination revealed that cilostazol ameliorated LPS-induced brain damage with reduced neuronal loss and gliosis. Immunohistochemistry analysis showed a decrease in Iba-1 expression, indicating a reduction in microglial activation in the cilostazol-Treated group compared to the LPS group. The findings advocate that cilostazol exerts neuroprotective effects against LPS-induced hippocampal injury by modulating the AKT/GSK3β/CREB pathway and curbing neuroinflammation. Cilostazol may hold promise as a therapeutic agent for neuroinflammatory conditions associated with neurodegenerative diseases.

AB - Neuroinflammation is important in the pathophysiology of several degenerative brain disorders. This study looked at the potential neuroprotective benefits of cilostazol, a phosphodiesterase inhibitor, against LPS-induced hippocampus damage in rodents and the principal molecular involvement of AKT/GSK3β/CREB signaling pathways. Behavioral tests revealed that cilostazol successfully corrected LPS-induced neurobehavioral impairments. Furthermore, cilostazol therapy lowered hippocampal levels of amyloid beta 1-42 (Aβ1-42) and p-Tau protein, both of which are critical pathological indicators of neurodegenerative disorders. Furthermore, cilostazol administration suppressed LPS-induced rises in hippocampus caspase-3 and NF-B levels while elevating rat B-cell/lymphoma 2 (BCL2) and brain-derived neurotrophic factor (BDNF) levels, which are implicated in neuronal survival and synaptic plasticity. Cilostazol treatment also restored the decreased phosphorylation of protein kinase B (p-AKT) and reduced the elevated levels of phosphorylated glycogen synthase kinase-3 beta (p-GSK3β) and cAMP response element-binding protein (CREB) in the hippocampus of LPS-Treated rats. Histopathological examination revealed that cilostazol ameliorated LPS-induced brain damage with reduced neuronal loss and gliosis. Immunohistochemistry analysis showed a decrease in Iba-1 expression, indicating a reduction in microglial activation in the cilostazol-Treated group compared to the LPS group. The findings advocate that cilostazol exerts neuroprotective effects against LPS-induced hippocampal injury by modulating the AKT/GSK3β/CREB pathway and curbing neuroinflammation. Cilostazol may hold promise as a therapeutic agent for neuroinflammatory conditions associated with neurodegenerative diseases.

UR - http://www.scopus.com/inward/record.url?scp=85207136954&partnerID=8YFLogxK

U2 - 10.1155/2024/3465757

DO - 10.1155/2024/3465757

M3 - Article

VL - 2024

JO - Advances in Pharmacological and Pharmaceutical Sciences

JF - Advances in Pharmacological and Pharmaceutical Sciences

IS - 1

M1 - 3465757

ER -

By the same author(s)